Download PDF
Horm Metab Res 2014; 46(04): 252-258
DOI: 10.1055/s-0034-1370933
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

A Key Role for Interferon Regulatory Factors in Mediating Early-Life Metabolic Defects in Male Offspring of Maternal Protein Restricted Rats

M. F. P. Silvestre
1   Centre for Diabetes, Bart’s and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
,
J. Kieswich
2   Department of Translational Medicine and Therapeutic, William Harvey Research Institute, Charterhouse Square, London, UK
,
M. M. Yaqoob
2   Department of Translational Medicine and Therapeutic, William Harvey Research Institute, Charterhouse Square, London, UK
,
M. J. Holness
1   Centre for Diabetes, Bart’s and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
,
M. C. Sugden
1   Centre for Diabetes, Bart’s and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
,
P. W. Caton
1   Centre for Diabetes, Bart’s and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
› Author Affiliations
Further Information

Publication History

received 30 October 2013

accepted 10 February 2014

Publication Date:
13 March 2014 (online)

Also available at
    Permissions and Reprints

Abstract

An adverse intra-uterine environment, induced by maternal consumption of diets high in saturated fat or low in protein have been implicated as a potential trigger for development of metabolic disease in later life. However, the underlying mechanisms responsible for this programming of obesity have yet to be described. Recent studies have demonstrated that interferon regulatory factors 3 (IRF3) and 4 (IRF4) function to repress adipogenesis. We investigated whether impaired IRF3 and IRF4 function may predispose to development of metabolic disease in a model of programmed obesity. Changes in IRF3 and IRF4 levels, adipogenic gene expression, and adiponectin signalling were measured in white adipose tissue from programmed male offspring of rat dams fed a low-protein diet (MLP), which are predisposed to obesity. 3T3L1 adipocytes were used to determine novel regulatory mechanisms governing IRF expression. IRF3 and IRF4 levels were suppressed in MLP rats, together with raised lipogenic and adipogenic gene expression. Adiponectin and adiponectin receptor 1 and 2 mRNA levels were reduced in MLP rats, along with levels of PPARα and activity of AMP-activated protein kinase (AMPK), 2 downstream targets of adiponectin. Further studies determined that both IRF3 and IRF4 are induced by adiponectin, with adiponectin-AMPK and adiponectin-PPARα signalling regulating IRF3 and IRF4, respectively. We have demonstrated that impaired ability to repress adipogenesis and lipogenesis, through dysregulated adiponectin-PPARα-AMPK-IRF signalling, may play a causal role in predisposing MLP offspring to development of obesity and metabolic disease in later life.

Key words

interferon regulatory factor - maternal low protein - adiponectin

Supporting Information

    for this article is available online at http:/www.thieme-connect.de/ejournals/toc/hmr
  • Supporting Information
 

  • References

  • 1 Cottrell EC, Ozanne SE. Early life programming of obesity and metabolic disease. Physiol Behav 2008; 94: 17-28
    CrossrefPubMedGoogle Scholar
  • 2 Fernandez-Twinn DS, Ekizoglou S, Wayman A, Petry CJ, Ozanne SE. Maternal low-protein diet programs cardiac beta-adrenergic response and signaling in 3-mo-old male offspring. Am J Physiol Regul Integr Comp Physiol 2006; 291: R429-R436
    CrossrefPubMedGoogle Scholar
  • 3 Barker DJ. Obesity and early life. Obes Rev 2007; 8 (Suppl. 01) 45-49
    CrossrefPubMedGoogle Scholar
  • 4 Holness MJ, Langdown ML, Sugden MC. Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of Type 2 diabetes mellitus. Biochem J 2000; 349: 657-665
    PubMedGoogle Scholar
  • 5 Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595-601
    CrossrefPubMedGoogle Scholar
  • 6 Forsen T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 2000; 133: 176-182
    PubMedGoogle Scholar
  • 7 Eguchi J, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, Estall JL, Klein U, Maratos-Flier E, Rosen ED. Transcriptional control of adipose lipid handling by IRF4. Cell Metab 2011; 13: 249-259
    CrossrefPubMedGoogle Scholar
  • 8 Eguchi J, Yan QW, Schones DE, Kamal M, Hsu CH, Zhang MQ, Crawford GE, Rosen ED. Interferon regulatory factors are transcriptional regulators of adipogenesis. Cell Metab 2008; 7: 86-94
    CrossrefPubMedGoogle Scholar
  • 9 Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55: 2562-2570
    CrossrefPubMedGoogle Scholar
  • 10 Bijland S, Mancini SJ, Salt IP. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013; 124: 491-507
    CrossrefPubMedGoogle Scholar
  • 11 Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009; 9: 327-338
    CrossrefPubMedGoogle Scholar
  • 12 Eguchi J, Kong X, Tenta M, Wang X, Kang S, Rosen ED. Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 2013; 62: 3394-3403
    CrossrefPubMedGoogle Scholar
  • 13 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirschman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174
    CrossrefPubMedGoogle Scholar
  • 14 Zhang T, Guan H, Arany E, Hill DJ, Yang K. Maternal protein restriction permanently programs adipocyte growth and development in adult male rat offspring. J Cell Biochem 2007; 101: 381-388
    CrossrefPubMedGoogle Scholar
  • 15 Bol VV, Reusens BM, Remacle CA. Postnatal catch-up growth after fetal protein restriction programs proliferation of rat preadipocytes. Obesity (Silver Spring) 2008; 16: 2760-2763
    CrossrefPubMedGoogle Scholar
  • 16 Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012; 55: 2319-2326
    CrossrefPubMedGoogle Scholar
  • 17 Qiao L, Lee B, Kinney B, Yoo HS, Shao J. Energy intake and adiponectin gene expression. Am J Physiol Endocrinol Metab 2011; 300: E809-E816
    CrossrefPubMedGoogle Scholar
  • 18 Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001; 50: 2809-2814
    CrossrefPubMedGoogle Scholar
  • 19 Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473-7478
    CrossrefPubMedGoogle Scholar
  • 20 Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001; 50: 411-417
    CrossrefPubMedGoogle Scholar
  • 21 Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X, Vázquez-Carrera M. The PPARb/d activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1a-Lipin 1-PPARa pathway leading to increased fatty acid oxidation. Endocrinology 2011; 152: 1848-1859
    CrossrefPubMedGoogle Scholar
  • 22 Holness MJ, Sugden PH, Silvestre MFP, Sugden MC. Actions and interactions of AMPK with insulin, the peroxisomal-proliferator activated receptors and sirtuins. Expert Rev Endocrinol Metab 2012; 7: 191-208
    CrossrefPubMedGoogle Scholar
  • 23 Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121: 2094-2101
    CrossrefPubMedGoogle Scholar
  • 24 Mittrücker HW, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997; 275: 540-543
    CrossrefPubMedGoogle Scholar